Regenxbio
RGNX
177 hedge funds and large institutions have $325M invested in Regenxbio in 2024 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 58 increasing their positions, 50 reducing their positions, and 44 closing their positions.
183% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $494K
16% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 50
3.44% less ownership
Funds ownership: 88.36% → 84.91% (-3.4%)
5% less funds holding
Funds holding: 186 → 177 (-9)
11% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 44
29% less capital invested
Capital invested by funds: $458M → $325M (-$133M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$15.6M |
| 2 |
Millennium Management
New York
|
+$9.96M |
| 3 |
Morgan Stanley
New York
|
+$6.14M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.69M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$4.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$31.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.64M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.61M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$5.49M |
RGNX Hedge Fund Activity: Q4 2024 in Review
177 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2024, worth a combined $325M — down 29% from $458M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of RGNX and 39 opened new positions — a net loss of 5 holders — while 50 trimmed existing stakes and 58 added.
The largest buyer was JP Morgan Chase, adding an estimated $15.6M. The largest seller was BlackRock, cutting an estimated $31.7M.
- 177 institutional investors held Regenxbio (RGNX) as of Q4 2024, down from 186 in Q3 2024.
- Funds reported $325M of Regenxbio stock for Q4 2024, down 29% quarter-over-quarter.
- 39 funds opened new Regenxbio positions in Q4 2024 and 44 closed out, a net change of -5 holders.
- The largest Regenxbio buyer in Q4 2024 was JP Morgan Chase, an estimated $15.6M added.
- The largest Regenxbio seller in Q4 2024 was BlackRock, an estimated $31.7M sold.
Based on aggregated 13F filings for Q4 2024.